Clinical Outcomes After Drug-Coated Balloon Treatment in Popliteal Artery Disease: K-POP Registry 12-Month Results

Overview

Journal Korean Circ J

Date 2024 May 20

PMID 38767445

Authors

Jong-Il Park

Young-Guk Ko

Seung-Jun Lee

Chul-Min Ahn

Seung-Woon Rha

Cheol-Woong Yu

Jong Kwan Park

Sang-Ho Park

Jae-Hwan Lee

Su-Hong Kim

Yong-Joon Lee

Sung-Jin Hong

Jung-Sun Kim

Byeong-Keuk Kim

Myeong-Ki Hong

Donghoon Choi

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: The popliteal artery is generally regarded as a "no-stent zone." Limited data are available on the outcomes of drug-coated balloons (DCBs) for popliteal artery disease. This study aimed to evaluate the 12-month clinical outcomes among patients who received DCB treatment for atherosclerotic popliteal artery disease.

Methods: This prospective, multicenter registry study enrolled 100 patients from 7 Korean endovascular centers who underwent endovascular therapy using IN.PACT DCB (Medtronic) for symptomatic atherosclerotic popliteal artery disease. The primary endpoint was 12-month clinical primary patency and the secondary endpoint was clinically driven target lesion revascularization (TLR)-free rate.

Results: The mean age of the study cohort was 65.7±10.8 years, and 77% of enrolled patients were men. The mean lesion length was 93.7±53.7 mm, and total occlusions were present in 45% of patients. Technical success was achieved in all patients. Combined atherectomy was performed in 17% and provisional stenting was required in 11%. Out of the enrolled patients, 91 patients completed the 12-month follow-up. Clinical primary patency and TLR-free survival rates at 12 months were 76.0% and 87.2%, respectively. A multivariate Cox regression analysis identified female and longer lesion length as the significant independent predictors of loss of patency.

Conclusions: DCB treatment yielded favorable 12-month clinical primary patency and TLR-free survival outcomes in patients with popliteal artery disease.

Trial Registration: ClinicalTrials.gov Identifier: NCT02698345.

Citing Articles

Should We Leave Something There?.

Lee C, Kim W Korean Circ J. 2024; 54(8):466-467.

PMID: 39109595 PMC: 11306423. DOI: 10.4070/kcj.2024.0182.

References

Goltz J, Ritter C, Kellersmann R, Klein D, Hahn D, Kickuth R . Endovascular treatment of popliteal artery segments P1 and P2 in patients with critical limb ischemia: initial experience using a helical nitinol stent with increased radial force. J Endovasc Ther. 2012; 19(3):450-6. DOI: 10.1583/11-3591MR.1. View

San Norberto E, Flota C, Fidalgo-Domingos L, Taylor J, Vaquero C . Real-World Results of Supera Stent Implantation for Popliteal Artery Atherosclerotic Lesions: 3-Year Outcome. Ann Vasc Surg. 2019; 62:397-405. DOI: 10.1016/j.avsg.2019.06.038. View

Stavroulakis K, Schwindt A, Torsello G, Stachmann A, Hericks C, Bosiers M . Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Isolated Popliteal Artery Lesions. J Endovasc Ther. 2016; 24(2):181-188. DOI: 10.1177/1526602816683933. View

Spiliopoulos S, Kitrou P, Galanakis N, Papadimatos P, Katsanos K, Konstantos C . Incidence and Endovascular Treatment of Isolated Atherosclerotic Popliteal Artery Disease: Outcomes from the IPAD Multicenter Study. Cardiovasc Intervent Radiol. 2018; 41(10):1481-1487. DOI: 10.1007/s00270-018-2028-7. View

Caradu C, Lakhlifi E, Colacchio E, Midy D, Berard X, Poirier M . Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. J Vasc Surg. 2019; 70(3):981-995.e10. DOI: 10.1016/j.jvs.2019.01.080. View

Kohi M, Brodmann M, Zeller T, Micari A, Baumgartner I, Wang H . Sex-Related Differences in the Long-Term Outcomes of Patients with Femoropopliteal Arterial Disease Treated with the IN.PACT Drug-Coated Balloon in the IN.PACT SFA Randomized Controlled Trial: A Post Hoc Analysis. J Vasc Interv Radiol. 2020; 31(9):1410-1418.e10. DOI: 10.1016/j.jvir.2020.05.012. View

Hoffmann U, Vetter J, Rainoni L, Leu A, Bollinger A . Popliteal artery compression and force of active plantar flexion in young healthy volunteers. J Vasc Surg. 1997; 26(2):281-7. DOI: 10.1016/s0741-5214(97)70190-3. View

Rastan A, McKinsey J, Garcia L, Rocha-Singh K, Jaff M, Harlin S . One-Year Outcomes Following Directional Atherectomy of Popliteal Artery Lesions: Subgroup Analysis of the Prospective, Multicenter DEFINITIVE LE Trial. J Endovasc Ther. 2017; 25(1):100-108. PMC: 5774616. DOI: 10.1177/1526602817740133. View

Torsello G, Stavroulakis K, Brodmann M, Micari A, Tepe G, Veroux P . Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort. J Endovasc Ther. 2020; 27(5):693-705. PMC: 7545651. DOI: 10.1177/1526602820931477. View

10.

Poulson W, Kamenskiy A, Seas A, Deegan P, Lomneth C, MacTaggart J . Limb flexion-induced axial compression and bending in human femoropopliteal artery segments. J Vasc Surg. 2017; 67(2):607-613. PMC: 5690897. DOI: 10.1016/j.jvs.2017.01.071. View

11.

Wu X, Peng Z, Qin J, Yang X, Lu X, Ye K . Outcomes of Drug-Coated Balloon Angioplasty for Isolated Chronic Occlusion of the Popliteal Artery: A Retrospective Single-Institution Study. J Vasc Interv Radiol. 2021; 32(4):593-601. DOI: 10.1016/j.jvir.2020.12.024. View

12.

Gokgol C, Diehm N, Kara L, Buchler P . Quantification of popliteal artery deformation during leg flexion in subjects with peripheral artery disease: a pilot study. J Endovasc Ther. 2013; 20(6):828-35. DOI: 10.1583/13-4332MR.1. View

13.

Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K . Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2011; 59(1):16-23. DOI: 10.1016/j.jacc.2011.09.036. View

14.

Kroger K, Santosa F, Goyen M . Biomechanical incompatibility of popliteal stent placement. J Endovasc Ther. 2004; 11(6):686-94. DOI: 10.1583/04-127.1. View

15.

McKinsey J, Zeller T, Rocha-Singh K, Jaff M, Garcia L . Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv. 2014; 7(8):923-33. DOI: 10.1016/j.jcin.2014.05.006. View

16.

Scheinert D, Werner M, Scheinert S, Paetzold A, Banning-Eichenseer U, Piorkowski M . Treatment of complex atherosclerotic popliteal artery disease with a new self-expanding interwoven nitinol stent: 12-month results of the Leipzig SUPERA popliteal artery stent registry. JACC Cardiovasc Interv. 2013; 6(1):65-71. DOI: 10.1016/j.jcin.2012.09.011. View

17.

Rastan A, Krankenberg H, Baumgartner I, Blessing E, Muller-Hulsbeck S, Pilger E . Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery: a prospective, multicenter, randomized trial. Circulation. 2013; 127(25):2535-41. DOI: 10.1161/CIRCULATIONAHA.113.001849. View

18.

Tamashiro G, Tamashiro A, Villegas M, Dini A, Mollon A, Zelaya D . Flexions of the popliteal artery: technical considerations of femoropopliteal stenting. J Invasive Cardiol. 2011; 23(10):431-3. View

19.

Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A . Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2014; 131(5):495-502. PMC: 4323569. DOI: 10.1161/CIRCULATIONAHA.114.011004. View

20.

Cummings P, Rivara F, Koepsell T . Writing informative abstracts for journal articles. Arch Pediatr Adolesc Med. 2004; 158(11):1086-8. DOI: 10.1001/archpedi.158.11.1086. View